Dan Kelly Laboratory

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The Kelly Lab is interested in the upstream transcriptional regulatory mechanisms and consequences of mitochondrial biogenesis and remodeling in the developing and diseased heart. A second major focus is the energy metabolic origins of disease.

The Kelly Lab's current projects include:

  • Cardiac nuclear receptor signaling in health and disease
  • Systems-based deep interrogation of mitochondrial reprogramming during development of cardiac hypertrophy and heart failure
  • Testing metabolic modulator therapies in pre-clinical models of heart failure
  • Delineation of mechanisms and signaling pathways involved in muscle metabolic fitness.

More information about the Kelly Lab can be found on the University of Pennsylvania web page.

The Kelly Lab has contributed to several research accomplishments:

  • Defined the genetic basis of human MCAD deficiency
  • Determined the transcriptional regulatory axis that controls cardiac mitochondrial function and fuel utilization
  • Demonstrated that PGC-1alpha drives cardiac mitochondrial biogenesis
  • Determined that the nuclear receptor ERR is essential for postnatal cardiac maturation and is dysregulated in the hypertrophied and failing heart
  • Discovered that the failing heart switches to using ketone bodies as a fuel
  • Demonstrated that ketone ester supplementation protects against heart failure.
Leader
Daniel P. Kelly

Daniel P. Kelly, MD